CTRI/2011/11/002132招募中未知
A prospective, double-masked, randomized, clinical trial to evaluate the efficacy of debridement in the treatment of keratoconjunctivitis caused by microsporidia.
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients presenting with clinically diagnosed superficial epithelial microsporidial keratitis or keratoconjunctivitis.
- •Minimum of 10 discrete epithelial or subepithelial lesions on presentation.
- •Must be able to read and sign an informed consent form or if the patient is under 18 years of age, the informed consent must be understood and signed by the patient?s parent or guardian.
- •Must agree to ensure compliance with the visit schedules and/or other requirements of the study, or the parents or guardians of patients less than 18 years of age must agree to ensure the above compliance.
排除标准
- •Any clinically diagnosed case of superficial microsporidial keratoconjunctivitis with less than 10 discrete lesions.
- •Presence of stromal infiltrates at presentation.
研究者
相似试验
尚未招募
不适用
A study comparing 2 drugs in reversal of general anaesthesiaCTRI/2023/10/058419SIMS hospitals, Department of anaesthesiology and pain management
招募中
2 期
Effects of Vitamin E Delta-tocotrienol supplementation in Nonalcoholic Fatty Liver Disease (NAFLD)onalcoholic fatty liver disease (NAFLD)SLCTR/2015/023Armed Forces Institute of Pathology, Pakistan
已完成
不适用
Bevacizumab versus ranibizumab in age-related macular degeneratioAge-related macular degenerationISRCTN73359806VA Boston Healthcare System (USA)125
进行中（未招募）
1 期
Phase II Study to Analyze Sarilumab in Non-Infectious UveitisveitisMedDRA version: 17.1Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2012-004845-34-DESanofi-aventis recherche et développement70
进行中（未招募）
1 期
Phase II Study to Analyze Sarilumab in Non-Infectious UveitisveitisMedDRA version: 16.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2012-004845-34-ITSanofi-aventis recherche et développement70